Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD177 Deficiency Defines a Stable Subtype of Human Neutrophil Granulocytes with Tumor Promoting Activity.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Patient Satisfaction and Supportive Care Pathways in a German Head and Neck Tumor Center: A Prospective Cross-Sectional Study.

Healthcare (Basel, Switzerland)·2026
Same author

In-Solution Characterization of Extracellular Vesicles: A New Approach to Evaluating Antibody Binding and Surface Interactions.

Journal of extracellular vesicles·2026
Same author

Cell-cycle-specific lesion evolution rather than inhibition of double-strand-break repair underpins cisplatin radiosensitization.

Molecular oncology·2026
Same author

Prognostic factors and cervical lymph node management in tongue squamous cell carcinoma: a retrospective cohort study.

Clinical oral investigations·2026
Same author

A New Subpopulation of Extracellular Vesicles Harvested from Osteogenically Induced Mesenchymal Stromal Cells of Surgical Site-Released Tissue.

Biomolecules·2026
Same journal

Bovine Milk-Derived Extracellular Vesicles as Emerging Drug Delivery Platforms: Current Advances, Applications and Challenges.

Journal of extracellular biology·2026
Same journal

Stage-Specific Molecular Cargo of Schwann Cell-Derived Extracellular Vesicles is Associated With Peripheral Nerve Repair.

Journal of extracellular biology·2026
Same journal

Cell Envelope Remodeling and Lipid Metabolism Coordinate Extracellular Vesicle Output in Mycobacterium Tuberculosis.

Journal of extracellular biology·2026
Same journal

Extracellular Vesicles of <i>Giardia duodenalis</i>: Unravelling Their Virulence Factors and Potential to Induce Protection Against Experimental Giardiasis.

Journal of extracellular biology·2026
Same journal

HIV Tat-Stimulated Microglial Extracellular Vesicles Are Enriched for Ferroptosis Mediators: Role of Dysregulated Autophagy.

Journal of extracellular biology·2026
Same journal

Extracellular Vesicle-Associated IL4 Displays Enhanced Anti-Inflammatory Properties in Microglial Cells.

Journal of extracellular biology·2026
See all related articles

Related Experiment Video

Updated: Jun 9, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Single-EV Analyses Require Rigorous Antibody Qualification: PD-L1 Profiling in Cell Models and Patient Plasma.

Tobias Tertel1, Fabiola Nardi Bauer1,2, Oumaima Stambouli1

  • 1Institute for Transfusion Medicine University Hospital Essen University of Duisburg-Essen Essen Germany.

Journal of Extracellular Biology
|June 8, 2026
PubMed
Summary
This summary is machine-generated.

Antibody performance is crucial for imaging flow cytometry (IFCM) of extracellular vesicles (EVs). This study developed a validated IFCM workflow for detecting PD-L1 positive EVs in patient plasma, highlighting the need for application-specific antibody validation.

Keywords:
PD‐L1antibody validationcancer plasmaextracellular vesiclesimaging flow cytometrysingle‐vesicle analysis

More Related Videos

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Related Experiment Videos

Last Updated: Jun 9, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Area of Science:

  • Extracellular vesicle (EV) research
  • Immunophenotyping
  • Biomarker discovery

Background:

  • Imaging flow cytometry (IFCM) offers high-throughput, single-vesicle analysis of extracellular vesicles (sEVs).
  • Antibody performance is critical for IFCM reliability and sensitivity in sEV detection.
  • Existing antibody validation for cellular targets may not translate to sEV analysis.

Purpose of the Study:

  • To systematically compare commercial anti-PD-L1 antibodies for sEV detection using IFCM.
  • To develop and validate a standardized IFCM workflow for sEV profiling.
  • To assess the potential of IFCM for semi-quantitative analysis of PD-L1 positive sEVs in patient plasma.

Main Methods:

  • Systematic comparison of anti-PD-L1 antibodies for labeling PD-L1 positive sEVs.
  • Development of a robust IFCM workflow adhering to MIFlowCyt-EV standards.
  • Application of the validated workflow to analyze PD-L1 positive sEVs in unprocessed plasma from cancer patients and healthy donors.
  • Comparison of IFCM with bead-based methods and dilution experiments for quantitative assessment.

Main Results:

  • Significant differences in labeling efficiency were observed among anti-PD-L1 antibodies from different manufacturers.
  • A validated IFCM workflow enabled reproducible detection of PD-L1 positive sEVs in patient plasma.
  • IFCM demonstrated semi-quantitative capability by revealing distinct PD-L1 positive sEV levels, unlike bead-based methods.
  • Elevated PD-L1 positive sEV levels were detected in plasma subsets from head and neck, lung, and breast cancer patients.

Conclusions:

  • Antibody suitability for sEV analysis requires rigorous, application-specific validation beyond standard cellular assays.
  • A standardized IFCM workflow provides a reliable method for single-EV profiling.
  • Elevated PD-L1 positive sEVs in cancer patient plasma suggest potential clinical relevance.
  • The quality of antibodies is paramount for accurate analytical results in single-EV studies.